Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

NCT03427151 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Systemic

Interventions

DRUG: IPP-201101

Sponsor

ImmuPharma